NCT06359379Phase 2Terminated

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Study sponsor: Shuttle Pharmaceuticals, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12-01Actual
Enrollment · participants30Actual
Source updated2025-12-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 54 participants (planned). After: 30 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2026. After: 1 Dec 2025.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview